Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients

Kidney International

Volumn 55, Issue 3, 1999, Pages 1072-1080

  Födinger, Manuela ^b   Wölfl, Gabriele ^b   Fischer, Gottfried ^b   Rasoul Rockenschaub, Susanne ^b   Schmid, Rainer ^b   Hörl, Walter H ^b   Sunder Plassmann, Gere ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Cardiovascular disease; Folate; Hyperhomocysteinemia; MTHFR; Polymorphism; Transplantation; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; FOLIC ACID BLOOD LEVEL; GENE EXPRESSION; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0005601318     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.0550031072.x     Document Type: Article

References (51)

1. Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration, in The Metabolic and Molecular Bases of Inherited Disease (vol 1), edited by Scriver CR, Beaudet AL, Sly WS, Valle D, New York, McGraw-Hill, 1995, pp 1279-1327
2. Harker LA, Slichter SJ, Scott CR, Ross R: Homocystinemia: Vascular injury and arterial thrombosis. N Engl J Med 291:537-543, 1974
3. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324:1149-1155, 1991
4. Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762, 1996
5. Duell PB, Malinow MR: Homocyst(e)ine: An important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 8:28-34, 1997
6. D'angelo A, Selhub J: Homocysteine and thrombotic disease. Blood 90:1-11, 1997
7. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, De Valk HW, Sales Luis AC, Parrot-Roulaud FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G: Plasma homocysteine as a risk factor for vascular disease: The European concerted action project. JAMA 277:1775-1781, 1997
8. Motulsky AG: Nutritional ecogenetics: Homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 58:17-20, 1996
9. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236, 1997
10. Robinson K, Mayer EL, Miller DP, Green R, Van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW: Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation 92:2825-2830, 1995
11. Verhoef P, Kok FJ, Kruyssen DACM, Schouten EG, Witteman JCM, Grobbee DE, Ueland PM, Refsum H: Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 17:989-995, 1997
12. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PWF, Selhub J: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 114:93-103, 1995
13. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743-2748, 1996
14. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 17:2554-2558, 1997
15. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97:138-141, 1998; correction: Circulation 97:711, 1998
16. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52:10-20, 1997
17. Wilcken DEL, Gupta VJ: Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 9:301-307, 1979
18. Wilcken DEL, Gupta VJ, Reddy SG: Accumulation of sulphurcontaining amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci 58:427-430, 1980
19. Kang SS, Wong PWK, Bidani A, Milanez S: Plasma protein-bound homocyst(e)ine in patients requiring chronic haemodialysis. Clin Sci 65:335-336, 1983
20. Smolin LA, Laidlaw SA, Kopple JD: Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis. Am J Clin Nutr 45:737-743, 1987
21. Soria C, Chadefaux B, Coude M, Gaillard O, Kamoun P: Concentrations of total homocysteine in plasma in chronic renal failure. Clin Chem 36:2137-2138, 1990
22. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 40:230-234, 1993
23. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43(Suppl 41):S72-S77, 1993
24. Bostom A, Brosnan JT, Hall B, Nadeau MR, Selhub J: Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116:59-62, 1995
25. Foreman JW, Wald H, Blumberg G, Pepe LM, Segal S: Homocystine uptake in isolated rat renal cortical tubules. Metabolism 31:613-619, 1982
26. McKeever MP, Weir DG, Molloy A, Scott JM: Betaine-homocysteine methyltransferase: Organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci 81:551-556, 1991
27. Gaull GE, Von Berg W, Räthä NCR, Sturman JA: Development of methyltransferase activities of human fetal tissues. Pediatr Res 7:527-533, 1973
28. Baumgartner ER, Stokstad ELR, Wick H, Watson JE, Kusano G: Comparison of folic acid coenzyme distribution patterns in patients with methylenetetrahydrofolate reductase and methionine synthetase deficiencies. Pediatr Res 91:1288-1292, 1985
29. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9, 1996
30. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123:193-202, 1996
31. Wilcken DEL, Dudman NP, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37:697-701, 1988
32. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
33. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D, Upson B, Lin QR: The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 17:1157-1162, 1997
34. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, Den Heijer M, Kluijtmans LAJ, Van Den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111-113, 1995
35. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, Conley MR, Weir DG, Scott JM: Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations. Lancet 349:1591-1593, 1997
36. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, Evans A, Graham IM, Whitehead AS: Homocysteine and risk of premature coronary heart disease: Evidence for a common gene mutation. Circulation 94:2154-2158, 1996
37. Kluijtmans LAJ, Van Den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, Van Oost BA, Den Heijer M, Trijbels FJM, Rozen R, Blom HJ: Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58:35-41, 1996
38. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow R, Willet WC, Rozen R: Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94:2410-2416, 1996
39. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest J, Rozen R: Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 17:569-573, 1997
40. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müleer E, Schmid R, Hörl WH, Sunder-Plassmann G: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52: 517-523, 1997
41. Vychytil A, Födinger M, Wölfl G, Enzenberger B, Auinger M, Prischl F, Buxbaum M, Wiesholzer M, Mannhalter C, Hörl WH, Sunder-Plassmann G: Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 53:1775-1782, 1998
42. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
43. Wilcken DEL, Gupta VJ, Betts AK: Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism. Clin Sci 61:743-749, 1981
44. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P,Thyssel H: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 61:509-512, 1996
45. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drüeke TB, Legendre C, Lacour B, Kamoun P, Kreis H: Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 9:1103-1108, 1994
46. Fogarty DG, Woodside J, Lightbody JH, Loughrey CM, Yarnell J, Young IS, Maxwell AP: Plasma homocysteine in renal transplant recipients. (abstract) J Am Soc Nephrol 7:1931, 1996
47. Bostom AG, Gohh RY, Tsai My, Hopkins-Garcia BJ, Nadeau MR, Bianchi LA, Jaques PF, Rosenberg IH, Selhub J: Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol 17:1894-1900, 1997
48. Arnadottir M, Hultberg B: Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients. (letter) Transplant 64:1087, 1997
49. Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jacques PF, Selhub J, Rosenberg IH: Treatment of hyperhomocysteinemia in renal transplant recipients: A randomized, placebo-controlled trial. Ann Int Med 127:1089-1092, 1997
50. Hörl WH, Riegel W, Wanner C, Haag-Weber M, Schollmeyer P, Wieland H, Wilms H: Endocrine and metabolic abnormalities following kidney transplantation. Klin Wochenschr 67:907-918, 1989
51. Nath KA: Homocysteine and atherothrombosis. (letter) N Engl J Med 339:478-479, 1998